Medication adherence in patients with schizophrenia: a means to an end
Kikkert, M.J.

Citation for published version (APA):
Kikkert, M. J. (2010). Medication adherence in patients with schizophrenia: a means to an end
Chapter 5

The Predictive Validity of Subjective Adherence Measures in Patients with Schizophrenia

Martijn J. Kikkert
Maarten W.J. Koeter
Jack J.M. Dekker
Lorenzo Burti
Debbie Robson
Bernd Puschner
Aart H. Schene

Accepted for publication in: The International Journal of Methods in Psychiatric Research
Abstract

Despite frequent use of subjective adherence measures in patients with schizophrenia as well as other chronic conditions, there are several reports that question the validity of these instruments. Three well known, representative subjective measures are the Medication Adherence Questionnaire (MAQ), the Drug Attitude Inventory (DAI), and the Compliance Rating Scale (CRS). In this study we explored the predictive validity of these instruments in a European sample of 119 stabilized outpatients with schizophrenia. Clinical outcome variables were relapse and admission to a psychiatric hospital during a follow up period of 12 months. Results indicate that the predictive validity of all three measures was poor. The MAQ was the least problematic predictor for relapse (Nagelkerke $R^2=0.09$), and time to relapse ($R^2=0.07$) and had the best sensitivity for relapse (63.6%) as well as admission (87.5%). The MAQ and CRS were both moderate predictive for admission (Nagelkerke $R^2=0.21$, and $R^2=0.29$). We conclude that the validity of the instruments studied here is questionable and have limited clinical relevance. Given the feasibility and ease of most subjective instruments, researchers may be tempted to use them but should be aware of the serious drawbacks of these instruments.
The predictive validity of subjective adherence measures

Introduction

Studies have shown that medication use in patients with chronic conditions is generally poor (Sabaté et al., 2003). This is found for physical conditions such as cardiovascular diseases and HIV, but also in patients suffering from chronic mental health diseases such as psychotic disorders. This undermines the potential therapeutic effect of antipsychotic medication resulting in increased burden for patients, family, and professionals, as well as major economical costs.

Our knowledge concerning prevalence, efficacy of adherence interventions, and determinants of non-adherence is based on studies performed in the last decades. These studies have one thing in common; their outcomes rely on a valid assessment of medication adherence. Several methods are available to measure medication adherence but the majority of adherence studies in schizophrenia, resort to subjective instruments, such as questionnaires or interviews that rely on self report or on assessments made by others (Velligan et al., 2006). An advantage of these instruments is that they are cheap, easy to use and non intrusive. Unfortunately the instruments are often not validated, are susceptible to error, misinterpretation or distortion, and the quality of their description varies but is often poor (Kane, 1983; Nichol et al., 1999; Nose et al., 2003; Osterberg & Blaschke, 2005; Velligan et al., 2006).

In a previous article (Kikkert et al., 2008) we examined concurrent validity of three frequently used, subjective adherence measures; the Medication Adherence Questionnaire (MAQ), the Drug Attitude Inventory (DAI), and the Compliance Rating Scale (CRS) (Hogan et al., 1983; Kemp et al., 1998; Morisky et al., 1986). Although all instruments claim to assess the degree of medication adherence, our results indicated that the instruments did not seem to measure the same concept. Also the overlap of patients labelled as non-adherent by the three instruments was limited. Based on these results we concluded that the concurrent validity was low and that it is very unlikely that all three validly assess adherence. This did however not preclude the possibility that one of these instruments is a valid measure of adherence.

Since these, and similar type of adherence measures, are so commonly used, this may have had an impact on the results of many studies. In this study we will further explore the validity of these instruments using the possible consequences of non-adherence; clinical deterioration and consequently psychiatric hospitalization as criterion. So far there is overwhelming evidence for the efficacy of antipsychotic medication (Ayuso-Gutierrez et al., 1997; Kahn et al., 2008; Keith et al., 2003; Lieberman et al., 2005; Morken et al.,
Sub therapeutic intake of medication is related to exacerbation of symptoms and relapse (Fenton, 1997; Robinson et al., 1999; Weiden & Zygmunt, 1997), and is the most important determinant for relapse in first episode psychosis patients (Malla et al., 2006).

A secondary, clinically relevant effect of adherence might be (Law et al., 2008). In comparison to relapse, the effect of non-adherence on admission is influenced by circumstantial factors such as patient characteristics (e.g. patient preference), social characteristics (e.g. family support and living conditions) and (mental) health care characteristics (e.g. number of beds available, policy, outpatient treatment facilities). Therefore not all patients that relapse will also be admitted to a psychiatric hospital. Nevertheless, several large scale studies using pharmacy data or electronic medication monitoring as an indicator of medication adherence showed that non-adherent patients had higher admission rates (Diaz et al., 2001; Eaddy et al., 2005; Gilmer et al., 2004; Valenstein et al., 2002; Weiden et al., 2004).

Some studies evaluated relapse or admission as outcome variable, in this study we are able to evaluate relapse, as well as admission of 119 stabilized outpatients with schizophrenia over a 12 month follow up period. The aim of this study is to determine the predictive validity of three often used measures of adherence, the MAQ, DAI and CRS. Clinical outcome will be defined in our study as a. risk of relapse and admission, and b. time to relapse and admission.

Methods

Study design
Data used in this study was collected during the QUATRO study (Quality of life following adherence therapy for people disabled by schizophrenia and their carers), an international randomised controlled trial assessing the efficacy of Adherence Therapy in patients with schizophrenia (Gray et al., 2006). The study was approved by all four local institutional medical ethical committees. During this study assessments were conducted at baseline and after 12 months. Ratings assessed at baseline were used in this study together with data on relapse and hospitalisation during the 12 month follow up period.
The predictive validity of subjective adherence measures

Participants

Patients were recruited in four European cities: London (UK), Verona (Italy), Leipzig (Germany) and Amsterdam (the Netherlands). Inclusion criteria were: 1) clinical diagnosis of schizophrenia according to ICD-10 criteria, confirmed by a research diagnosis of schizophrenia using the Item Group checklist (IGC) of the Schedule for Clinical Assessment in Neuropsychiatry (Wing et al., 1990), 2) in need of maintenance anti-psychotic treatment for at least one year after entry into the study, and 3) evidence of clinical instability in the previous year (at least one hospital admission on clinical, mental health grounds, a change in anti-psychotic medication, increased frequency of planned or actual contact, indications of clinical instability from relatives, carers or clinical team). Exclusion criteria were: 1) moderate or severe learning disabilities, 2) organic brain disorders and 3) treatment by forensic psychiatric services.

Approximately one third of patients are treatment resistant (Conley & Kelly, 2001; Kane 1996, 1999), ranging from persistent disabling symptoms despite adequate trials of medication, up to the absence of any medication benefit. For treatment resistant patients the assumed causal relation between medication adherence and relapse does not apply. In this study only outpatients, free of positive symptoms during the time of assessment were included for analysis. This ruled out the inclusion of treatment resistant patients. It also enabled us to examine the risk of relapse and psychiatric admission. The effect of antipsychotic medication on negative symptoms is limited and was therefore not incorporated as selection criterion or outcome variable. In the QUATRO study, there were no differences found between the treatment and control group on any of the outcome variables such as: the score on the MAQ, DAI and CRS, the risk for relapse or hospitalisation, psychopathology as measured with the Expanded Brief Psychiatric Rating Scale (BPRS-E), or insight as measured with the expanded version of the Schedule for Assessment of Insight (Gray et al., 2006). All patients were therefore considered eligible for this study and treatment arm was not incorporated as a confounder.

After screening, 917 patients from four European countries were found eligible for the QUATRO study. Approximately a third of these patients (N=366) refused to participate, and 142 patients could not be included for other reasons (Gray et al., 2006). Out of the 409 included patients in the QUATRO study, analysis in this study were based on 119 stabilized outpatients with schizophrenia who gave written informed consent. At baseline, 80 patients stayed in an inpatient setting or psychiatric hospital, and 148 outpatients were psychotic. A patient was rated psychotic if moderate to extremely severe positive symptoms, according to the BPRS-E, were present for at least one week. This was
rated by the clinician. Finally, 62 patients were excluded for analysis because their clinical course data was incomplete (covered <90% of the follow up period).

**Instruments**

All instruments were administered once at baseline. Starting at baseline, clinical course was recorded during the follow up period of 12 months.

**Clinical course rating**

Although there are no clear criteria for relapse, in accordance with Johnstone’s (1992) definition, we defined relapse in this paper as reappearance of positive symptoms. For this purpose we used an instrument which was constructed to identify clinical course patterns of patients (Burti et al., 2008). Clinicians were asked to rate if a patient was psychotic for each quarter of a month. Clinical course ratings were given for the entire follow up period of twelve months. As described above, patients were rated psychotic if moderate to extremely severe positive symptoms, according to the BPRS-E, were present for at least one week. Psychotic episodes were considered separate if they were interrupted by a non-psychotic period of at least one month. Admissions to a psychiatric hospital were scored similarly on this instrument. Hospital admissions were considered separate if the time between two admissions was at least half a month (Burti et al., 2008).

**Adherence instruments**

For each patient adherence was assessed with two self report scales, the MAQ and the DAI, and one clinician rated adherence scale, the CRS.

The MAQ consists of four yes/no questions and addresses ways in which patients may fail to take their prescribed medication: forgetting, carelessness, stopping the drug when they feel better and or stopping the drug because they believe it makes them feel worse (Morisky et al., 1986). A higher score on the MAQ indicates less problems with medicine taking and better adherence behaviour.

The DAI is a self report measure comprising ten yes/no statements reflecting patients’ experiences, attitudes and beliefs about medication. This 10-items version of the DAI was designed to assess medication adherence in patients with schizophrenia. Based on a validation study, 10 items were selected from the original 30 DAI-items as having maximal group discrimination of adherent and non-adherent patients (Hogan et al., 1983). Patients are asked to decide whether statements apply to them. Higher scores indicate a more positive attitude towards medication, and better adherence behaviour.
The CRS is used to rate medication adherence on a 7-point scale. The CRS is scored by key workers. Complete refusal is rated 1, patients who partially refuse score 2, patients who reluctantly or passively accept treatment score 3, 4 or 5 and patients who moderately or actively accept treatment score 6 or 7. For each score a brief description of adherence behaviour is provided in the questionnaire. A detailed description of statistical characteristics of these instruments is given in Kikkert et al. (2008).

For some analysis we classified patients as adherent or non-adherent using standard cut off criteria if available. For the MAQ, patients with a score ≤3 are defined as non-adherent (George et al., 2000; Morisky et al., 1986; Roth & Ivey, 2005). For the CRS, patients with a score ≤4 are considered non-adherent (Byerly et al., 2005; Kemp & David, 1996; Kemp et al., 1998; Mutsatsa et al., 2003). For the DAI, the sum of the negative items are subtracted from the sum of the positive items. If the resulting score is less than or equal to zero, patients are considered to be non-adherent (Hogan et al., 1983).

**Other instruments**

Other instruments used in this study were:
- the Expanded Brief Psychiatric Rating Scale (BPRS-E): this instrument consists of 24 items measuring the following dimensions: positive symptoms, negative symptoms, depression/anxiety and disorganization (Ruggeri et al., 2005).
- the expanded version of the Schedule for Assessment of Insight (SAI-E): this is a semi structured interview measuring three dimensions of insight: awareness of illness, relabelling of psychotic symptoms and treatment compliance (David, 1990; Kemp et al., 1998). Finally, information on type and dosage of prescribed antipsychotic medication was provided by the patient’s clinician.

**Analysis**

We explored sensitivity and specificity of the three instruments for relapse and psychiatric admission. Logistic regression analyses were used to study the relation between the continuous adherence ratings at baseline and psychotic relapse, and psychiatric admission during the follow up period. We used a Cox Regression analysis to explore time to relapse and time to admission. Before Cox Regressions were performed we formally tested the proportional hazard assumption by adding an intervention by time interaction term to the regression model (Kleinbaum, 1990). None of the regression coefficients of this
interaction term were statistically significant. Consequently, the proportional hazard assumption was met. To correct for multiple testing alpha was set at 0.017.

In the regression analyses a number of potential confounders were included as covariates. These confounders were all variables determined as risk factor for non-adherence based on literature reviews. For a detailed description see our previous paper (Kikkert et al., 2008). Potential confounders were: living situation, medication efficacy, psychopathology; functioning, illness insight, medication side effects, type of antipsychotic (first or second generation, and depot), antipsychotic dose and frequency, and number of prescribed psychotropic agents. Based on the change-in-estimate strategy (Maldonado & Greenland, 1993; Rothman & Greenland, 1998; Sonis, 1998), confounders were included in the analysis if, when added to the Cox regression model, the odds ratio for any of the adherence instruments changed more than 10%. Positive symptoms (measured with the BPRS-E) fulfilled this criterion but was not included as a confounder because we considered it part of the causal pathway between adherence and outcome. The following confounders were included: negative symptoms (subscale negative symptoms of the BPRS-E), insight; symptom relabelling and hypothetical contradiction (factor 1 of the SAI-E), insight; illness awareness (factor 2 of the SAI-E), and depot medication.

**Results**

Social-demographic characteristics and clinical outcomes for all included patients are shown in Table 1. Patients were middle aged, a slight majority was male, and relatively few were employed or married. On average patient’s had been prescribed antipsychotic medication for approximately 13 years. The sample in this study showed no differences compared to the remaining outpatients in the QUATRO study on any of the socio-demographic characteristics, except for ethnicity. In our sample we had less Caucasians (63.0%) compared to the remaining outpatients in the QUATRO sample (85.2%). We also found that our sample had less severe psychiatric symptoms (mean BPRS-E total score of 38.4 compared with 48.4) which is probably due to excluding patients who were psychotic at baseline. Compared with the characteristics of more then 8000 outpatients with schizophrenia in two other European multicenter studies; the SOHO study (Haro et al., 2006) and the EPSILON study (Ruggeri et al., 2005), characteristics of our sample showed no differences. We therefore conclude that patients in this study form a
representative sample of stabilized western European outpatients with schizophrenia who
had been clinically instable in the previous year.

During the 12-month follow up period, 57 (48%) patients experienced psychotic
symptoms severe enough to define it a relapse. On average, the monthly relapse rate was
5.3%. Each quarter 15 patients (13%) relapsed, except for the last quarter in which 12
patients relapsed (10%). Most patients (79%) who experienced a psychotic period had
only one episode, and 18% had two episodes. Two patients had respectively 3 and 5
separate psychotic episodes. Out of the 57 patients with a relapse, 16 (28%) patients were
admitted to a psychiatric hospital. The average monthly admission rate in our sample
was 1.2%. Each quarter between 3 and 5 patients were admitted. Two patients (13%)
were admitted twice and one patient (6%) had three separate admissions. Most admitted
patients (81%) were admitted once.

Logistic regression analysis shows that the risk for relapse decreases with increasing
adherence rates. This relation was found for all three adherence measures but was only
significant for the MAQ (see Table 2). Besides a slight increase in risk of relapse, time to
relapse is shorter for patients with lower adherence rates. Again this was only significant
for the MAQ (see Table 3). For both analyses the explained variation ranges from 0.05
to 0.09, which in terms of Cohen's effect size criteria for $R^2$, is an indication for a low to
medium effect (Cohen, 1988).

The risk for admission also decreases with increasing adherence rates. Although this
relation was found for all three adherence instruments, it was only significant for the
MAQ and CRS (see Table 2). Time to admission is shorter for non-adherent patients but
this was only significant for the CRS (see Table 3). Explained variation for chance of, and
time to admission ranges from 0.10 to 0.29, which in terms of Cohen's effect size criteria
for $R^2$, an indication for a medium to strong effect (Cohen, 1988).
Table 1. Characteristics of sample (n=119)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>40.7 (11.66)</td>
</tr>
<tr>
<td>Male, N (%)</td>
<td>68 (57.1%)</td>
</tr>
<tr>
<td>Ethnicity, Caucasian, N (%)</td>
<td>75 (63.0%)</td>
</tr>
<tr>
<td>Single / unmarried, N (%)</td>
<td>107 (89.9%)</td>
</tr>
<tr>
<td>Paid or self employed, N (%)</td>
<td>20 (16.8%)</td>
</tr>
<tr>
<td>Living alone, with/without children, N (%)</td>
<td>68 (54.0%)</td>
</tr>
<tr>
<td>Years antipsychotic(s) prescribed, mean (SD)</td>
<td>13.17 (9.92)</td>
</tr>
<tr>
<td>Highest completed level of education, N (%)</td>
<td></td>
</tr>
<tr>
<td>Primary education or less</td>
<td>20 (16.9%)</td>
</tr>
<tr>
<td>Secondary education</td>
<td>58 (49.2%)</td>
</tr>
<tr>
<td>Tertiary/further education</td>
<td>40 (33.9%)</td>
</tr>
<tr>
<td>BPRS-E total score, mean (SD)</td>
<td>38.36 (12.04)</td>
</tr>
<tr>
<td>Psychotic relapse during follow up, N (%)</td>
<td>57 (47.9%)</td>
</tr>
<tr>
<td>Number of separate psychotic episodes, mean (SD) (N=57)</td>
<td>1.28 (0.67)</td>
</tr>
<tr>
<td>Duration between baseline and (first) episode in months, mean (SD) (N=57)</td>
<td>6.10 (3.26)</td>
</tr>
<tr>
<td>Duration of (first) psychotic episode in months, mean (SD) (N=57)</td>
<td>2.05 (1.81)</td>
</tr>
<tr>
<td>Hospitalized during follow up, N (%)</td>
<td>16 (13.4%)</td>
</tr>
<tr>
<td>Number of admissions, mean (SD) (N=16)</td>
<td>1.25 (0.58)</td>
</tr>
<tr>
<td>Duration between baseline and (first) admission in months, mean (SD) (N=16)</td>
<td>6.08 (3.29)</td>
</tr>
<tr>
<td>Duration of (first) admission in months, mean (SD) (N=16)</td>
<td>3.24 (2.60)</td>
</tr>
</tbody>
</table>
The predictive validity of subjective adherence measures

Table 2. Prediction of relapse and admission

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>S.E.</th>
<th>Wald</th>
<th>Sig.</th>
<th>Exp(B)</th>
<th>95% CI</th>
<th>Nagel-kerke</th>
<th>N</th>
<th>-2 log likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAQ</td>
<td>-0.613</td>
<td>0.231</td>
<td>7.054</td>
<td>0.008</td>
<td>0.542</td>
<td>0.345-0.852</td>
<td>0.092</td>
<td>93</td>
<td>109.000</td>
</tr>
<tr>
<td>DAI</td>
<td>-0.120</td>
<td>0.106</td>
<td>1.296</td>
<td>0.255</td>
<td>0.887</td>
<td>0.721-1.091</td>
<td>0.059</td>
<td>92</td>
<td>111.178</td>
</tr>
<tr>
<td>CRS</td>
<td>-0.345</td>
<td>0.173</td>
<td>3.962</td>
<td>0.047</td>
<td>0.708</td>
<td>0.505-0.995</td>
<td>0.072</td>
<td>88</td>
<td>110.321</td>
</tr>
</tbody>
</table>

Table 3. Prediction of time to relapse and admission

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>S.E.</th>
<th>Wald</th>
<th>Sig.</th>
<th>Exp(B)</th>
<th>95% CI lower</th>
<th>95% CI upper</th>
<th>Rp²</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAQ</td>
<td>-0.378</td>
<td>0.124</td>
<td>9.256</td>
<td>0.002</td>
<td>0.685</td>
<td>0.537</td>
<td>0.874</td>
<td>0.068</td>
<td>93</td>
</tr>
<tr>
<td>DAI</td>
<td>-0.096</td>
<td>0.066</td>
<td>2.121</td>
<td>0.145</td>
<td>0.908</td>
<td>0.798</td>
<td>1.034</td>
<td>0.052</td>
<td>92</td>
</tr>
<tr>
<td>CRS</td>
<td>-0.219</td>
<td>0.101</td>
<td>4.683</td>
<td>0.030</td>
<td>0.803</td>
<td>0.659</td>
<td>0.980</td>
<td>0.048</td>
<td>88</td>
</tr>
</tbody>
</table>

Table 4 shows the sensitivity and specificity of the three instruments to detect non-adherence. Both the DAI and CRS label most patients as adherent (respectively 86% and 79%) and therefore sensitivity is low while specificity is high. Compared to the DAI and CRS, the MAQ has better sensitivity and specificity.
Table 4. Sensitivity and specificity for relapse and admission (n=119)

<table>
<thead>
<tr>
<th></th>
<th>relapse sensitivity (%)</th>
<th>relapse specificity (%)</th>
<th>admission sensitivity (%)</th>
<th>admission specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAQ</td>
<td>63.6</td>
<td>59.7</td>
<td>87.5</td>
<td>54.5</td>
</tr>
<tr>
<td>DAI</td>
<td>18.2</td>
<td>90.0</td>
<td>20.0</td>
<td>87.0</td>
</tr>
<tr>
<td>CRS</td>
<td>34.0</td>
<td>90.3</td>
<td>38.5</td>
<td>81.8</td>
</tr>
</tbody>
</table>

Discussion

In our previous study (Kikkert et al., 2008) we concluded that concurrent validity of the MAQ, DAI and CRS was low. However this did not rule out the possibility that one of them is a good index of medication adherence. To explore this possibility, we evaluated the predictive validity of these three measures in this study.

There is significant evidence for the efficacy of antipsychotic medication. Therefore, in a sample of responsive stabilized outpatients, it seems reasonable to assume a relationship between medication intake behaviour and clinical outcome. In this study we found that the MAQ was predictive for relapse and for time to relapse. The MAQ and CRS were both predictive for hospital admission. The CRS was also predictive for time to hospital admission. The clinical relevance of these effects is however limited. Adherence rates on any of the three measures could only explain a relatively small proportion of the variation. Although non-adherent patients in general had higher relapse and admission rates, sensitivity shows that out of all patients who relapsed or got admitted, the proportion labelled as non-adherent was very low. Although sensitivity and specificity of the MAQ was better, 42% of patients who were non-adherent according to the MAQ still did not relapse, and 35% of adherent patients did relapse.

Out of the two self report instruments, the DAI had the worst predictive validity. The DAI focuses on patient’s attitudes towards medication whereas the MAQ items directly relate to medication intake behaviour. The latter seemed to be a slight better approach in measuring adherence, although Karow et al. (2007) found that subjective well being may also be useful in predicting adherence.

Other studies demonstrated that clinician ratings of adherence have poor validity (Byerly et al., 2005, 2007; Remington et al., 2007). Our results confirm this finding.Clinicians performed relatively better at estimating adherence behaviour of patients with...
poorer outcome defined as admission to hospital. In addition to more severe symptoms, patients who get admitted often have less social support and live alone. These are also associated with non-adherence (Fenton, 1997; Pinikahana et al., 2002; Perkins 2002) which may help explain why patients with high risk profiles for non-adherence are more easily detected by clinicians.

This study, however, also has its limitations. In a cohort study, Valenstein et al., (2006) examined adherence behaviour in two consecutive years and found that 83% of adherent patients, and 70% of non-adherent patients remained respectively adherent and non-adherent the following year. This may indicate that adherence is relatively stable for the majority of patients over two consecutive years. Nevertheless, in our study we only measured adherence at baseline and are unaware of any changes later in time. Patients may have changed their adherence behaviour after the baseline measurement. Patients who suffered mild or no symptoms may be more tempted to stop using their medication. On the other hand, patients who experienced exacerbation of symptoms due to non-adherence may have avoided relapse or hospitalization by increasing their medication intake in time. To reduce the influence of possible changes in adherence behaviour in time, we repeated our logistic regression analysis focusing only on relapses that occurred within the first 3, and 6 months. This did not change our results, none of the instruments were predictive for relapse in the first 3 or 6 months.

If a clinician was not sure about the patients condition over a certain period of time, the information on the clinical course rating was left blank. Nevertheless, the validity of the clinical course rating is not known and information regarding psychotic relapse can be affected by misinterpretation. This is not the case for admission data, which are therefore less likely to be inaccurate.

It is possible that a psychosis was induced by other causes such as life events or drug abuse. Although this would have strengthened our design, this information was not available for our sample. We do know from other studies that the increased risk for psychosis in drug abusers is at least partly due to non-adherence (Ascher-Svanum 2006; Perkins et al., 2008).

Relapse could also have been caused if inadequate doses of antipsychotic medication were prescribed. In our analysis, the daily dosage, expressed as the proportion of the defined daily doses of antipsychotic medication (WHO, 2003), turned out to have no influence on chance of, or time to relapse or admission. Therefore we conclude that patients in our sample received appropriate doses of medication.
Up to date subjective self report tests are the most frequently used methods to measure adherence. Although there is a wide variety of measures available, most of them are similar to either the MAQ, DAI or CRS. In a previous paper (Kikkert et al., 2008) we demonstrated that the MAQ, CRS and DAI do not measure the same trait. In this article we were able to determine the predictive validity in a European sample of treated stabilized outpatients with schizophrenia based on two significant clinical outcomes; relapse and admission. We found that none of the three instruments were able to clearly distinguish patients who are likely to relapse or get admitted to hospital in the following 12 months. Given the results of this study and our previous study (Kikkert et al., 2008) we conclude that the MAQ, CRS and DAI do not validly measure adherence and their use for scientific purposes is questionable. Unfortunately, the majority of adherence studies in patients with schizophrenia use these, or similar type of instruments. Researchers should be aware of the poor validity of subjective instruments and the impact it may have on study results. Given the convenience of subjective instruments, researchers should continue to strive for the development of valid, and easy to use adherence measures. Until these are available, objective instruments such as electronic medication monitoring, pill count or pharmacy based measures may be more preferable.

Acknowledgements
The QUATRO study is a multi-centre collaboration between the Health Services Research Department, Institute of Psychiatry, King's College London; the Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology; University of Verona, Italy; the Department of Psychiatry, Leipzig University, and the Department of Psychiatry II, Ulm University, Germany; and the Department of Psychiatry, Academic Medical Center, University of Amsterdam, Netherlands. The study was funded by a grant from the Quality of Life and Management of Living Resources Programme of the European Union (QLG4-CT-2001-01734). The views expressed in this publication are those of the authors and not necessarily those of the funders. We also wish to acknowledge the contributions of the patients, carers, and staff who have taken part in this study. We would like to acknowledge the contributions to this study of the following colleagues: Amsterdam Site (Aart Schene, Annemarie Fouwels, Martijn Kikkert, Maarten Koeter, Karin Meijer). Leipzig/Ulm Site (Thomas Becker, Matthias Angermeyer, Anja Born, Anne Gießler, Hedda Helm, Bernd Puschner). London Site (Jonathan Bindman, Jayne Camara, Anthony David, Kevin Gournay, Richard Gray, Martin Knapp, Morven Leese, Paul McCrone, Mauricio Moreno, Anita Patel, Debbie Robson, Graham Thornicroft, Ian
The predictive validity of subjective adherence measures

White). Verona Site (Michele Tansella, Francesco Amaddeo, Corrado Barbui, Lorenzo Burri, Daniela Celani, Doriana Cristofalo, Claudia Goss, Antonio Lasalvia, Giovanna Marrella, Mariangela Mazzi, Michela Nosè, Mirella Ruggeri, Marta Solfa).

Declaration of Interests
The authors have no competing interests.
References


The predictive validity of subjective adherence measures


Valenstein M, Copeland LA, Blow FC, et al. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care, 40: 630-639.


